PRMT5 and neoplasm: Tumor cells with MTAP deficiency can also be successfully targeted by inhibitors of methionine adenosyltransferase II, alpha (MAT2A), and protein arginine N-methyltransferase 5 (PRMT5) (summarized in [7]).